Abstract
The transcription factor p53 (also known as TP53) guards against tumour and virus replication and is inactivated in almost all cancers. p53-activated transcription of target genes is thought to be synonymous with the stabilization of p53 in response to oncogenes and DNA damage. During adenovirus replication, the degradation of p53 by E1B-55k is considered essential for p53 inactivation, and is the basis for p53-selective viral cancer therapies. Here we reveal a dominant epigenetic mechanism that silences p53-activated transcription, irrespective of p53 phosphorylation and stabilization. We show that another adenoviral protein, E4-ORF3, inactivates p53 independently of E1B-55k by forming a nuclear structure that induces de novo H3K9me3 heterochromatin formation at p53 target promoters, preventing p53–DNA binding. This suppressive nuclear web is highly selective in silencing p53 promoters and operates in the backdrop of global transcriptional changes that drive oncogenic replication. These findings are important for understanding how high levels of wild-type p53 might also be inactivated in cancer as well as the mechanisms that induce aberrant epigenetic silencing of tumour-suppressor loci. Our study changes the longstanding definition of how p53 is inactivated in adenovirus infection and provides key insights that could enable the development of true p53-selective oncolytic viral therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Change history
24 January 2023
A Correction to this paper has been published: https://doi.org/10.1038/s41586-022-05494-3
References
Levine, A. J. The common mechanisms of transformation by the small DNA tumor viruses: the inactivation of tumor suppressor gene products: p53. Virology 384, 285–293 (2009)
Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261–263 (1979)
Linzer, D. I. & Levine, A. J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 43–52 (1979)
Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000)
Vousden, K. H. & Prives, C. Blinded by the light: the growing complexity of p53. Cell 137, 413–431 (2009)
Kubbutat, M. H., Jones, S. N. & Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 387, 299–303 (1997)
Lowe, S. W. & Ruley, H. E. Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev. 7, 535–545 (1993)
Lakin, N. D. & Jackson, S. P. Regulation of p53 in response to DNA damage. Oncogene 18, 7644–7655 (1999)
Sherr, C. J. Divorcing ARF and p53: an unsettled case. Nature Rev. Cancer 6, 663–673 (2006)
Chen, X., Ko, L. J., Jayaraman, L. & Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10, 2438–2451 (1996)
Lane, D. P. Exploiting the p53 pathway for the diagnosis and therapy of human cancer. Cold Spring Harb. Symp. Quant. Biol. 70, 489–497 (2005)
Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844–848 (2004)
Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996)
Debbas, M. & White, E. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev. 7, 546–554 (1993)
Harada, J. N., Shevchenko, A., Pallas, D. C. & Berk, A. J. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J. Virol. 76, 9194–9206 (2002)
Querido, E. et al. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 15, 3104–3117 (2001)
Berk, A. J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 24, 7673–7685 (2005)
Barker, D. D. & Berk, A. J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107–121 (1987)
Khuri, F. R. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nature Med. 6, 879–885 (2000)
McCormick, F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol. Ther. 2, S157–S160 (2003)
O’Shea, C. C. et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6, 611–623 (2004)
O’Shea, C. C., Soria, C., Bagus, B. & McCormick, F. Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 8, 61–74 (2005)
Ries, S. J. et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nature Med. 6, 1128–1133 (2000)
Olsson, A., Manzl, C., Strasser, A. & Villunger, A. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ. 14, 1561–1575 (2007)
Espinosa, J. M., Verdun, R. E. & Emerson, B. M. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol. Cell 12, 1015–1027 (2003)
Gannon, J. V., Greaves, R., Iggo, R. & Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9, 1595–1602 (1990)
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W. & Vogelstein, B. Definition of a consensus binding site for p53. Nature Genet. 1, 45–49 (1992)
Kouzarides, T. Chromatin modifications and their function. Cell 128, 693–705 (2007)
Bachman, K. E. et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. Cancer Cell 3, 89–95 (2003)
Peters, A. H. et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107, 323–337 (2001)
Rice, J. C. et al. Histone methyltransferases direct different degrees of methylation to define distinct chromatin domains. Mol. Cell 12, 1591–1598 (2003)
Wang, H. et al. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol. Cell 12, 475–487 (2003)
Tachibana, M. et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev. 16, 1779–1791 (2002)
Whyte, P. et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 334, 124–129 (1988)
Ferrari, R. et al. Epigenetic reprogramming by adenovirus e1a. Science 321, 1086–1088 (2008)
Horwitz, G. A. et al. Adenovirus small e1a alters global patterns of histone modification. Science 321, 1084–1085 (2008)
O’Shea, C. C. Viruses – seeking and destroying the tumor program. Oncogene 24, 7640–7655 (2005)
Doucas, V. et al. Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. Genes Dev. 10, 196–207 (1996)
Stracker, T. H., Carson, C. T. & Weitzman, M. D. Adenovirus oncoproteins inactivate the Mre11–Rad50–NBS1 DNA repair complex. Nature 418, 348–352 (2002)
Yondola, M. A. & Hearing, P. The adenovirus E4 ORF3 protein binds and reorganizes the TRIM family member transcriptional intermediary factor 1 alpha. J. Virol. 81, 4264–4271 (2007)
Stott, F. J. et al. The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001–5014 (1998)
Johnson, L. et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1, 325–337 (2002)
Jones, N. & Shenk, T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl Acad. Sci. USA 76, 3665–3669 (1979)
Shepard, R. N. & Ornelles, D. A. E4orf3 is necessary for enhanced S-phase replication of cell cycle-restricted subgroup C adenoviruses. J. Virol. 77, 8593–8595 (2003)
Halbert, D. N., Cutt, J. R. & Shenk, T. Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J. Virol. 56, 250–257 (1985)
Cutt, J. R., Shenk, T. & Hearing, P. Analysis of adenovirus early region 4-encoded polypeptides synthesized in productively infected cells. J. Virol. 61, 543–552 (1987)
Huang, M. M. & Hearing, P. Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection. J. Virol. 63, 2605–2615 (1989)
Marcellus, R. C. et al. Adenovirus type 5 early region 4 is responsible for E1A-induced p53-independent apoptosis. J. Virol. 70, 6207–6215 (1996)
Martens, J. H. et al. The profile of repeat-associated histone lysine methylation states in the mouse epigenome. EMBO J. 24, 800–812 (2005)
Maehara, K. et al. Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. J. Cell Biol. 168, 553–560 (2005)
Eberhardy, S. R. & Farnham, P. J. c-Myc mediates activation of the cad promoter via a post-RNA polymerase II recruitment mechanism. J. Biol. Chem. 276, 48562–48571 (2001)
Downey, T. Analysis of a multifactor microarray study using Partek genomics solution. Methods Enzymol. 411, 256–270 (2006)
Bolstad, B. M., Irizarry, R. A., Astrand, M. & Speed, T. P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19, 185–193 (2003)
Irizarry, R. A. et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 31, e15 (2003)
Berriz, G. F., King, O. D., Bryant, B., Sander, C. & Roth, F. P. Characterizing gene sets with FuncAssociate. Bioinformatics 19, 2502–2504 (2003)
Yan, B. et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol. 8, R78 (2007)
Quandt, K., Frech, K., Karas, H., Wingender, E. & Werner, T. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res. 23, 4878–4884 (1995)
Hoh, J. et al. The p53MH algorithm and its application in detecting p53-responsive genes. Proc. Natl Acad. Sci. USA 99, 8467–8472 (2002)
Acknowledgements
We thank J. Fitzpatrick and the Waitt Advanced Biophotonics Center for assistance with imaging and analysis, J. Karlseder, I. Verma, T. Hunter, R. Shaw and the O’Shea laboratory for critical reading of this manuscript, L. Haro, S. Panda, R. O’Sullivan and A. Rodriguez for advice and protocols, and P. Branton and D. Ornelles for viruses. C.C.O. acknowledges funding from the Alliance of Cancer Gene Therapy, the American Cancer Society, the Sontag Foundation and the Beckman Foundation. This work was supported by R01CA137094 from the National Cancer Institute.
Author information
Authors and Affiliations
Contributions
C.S. performed the p53 activation and virus studies, including immunoblotting, RT–qPCR and microarray experiments. F.E.E. performed all chromatin immunoprecipitation and immunofluorescence studies. K.C.E. performed the luciferase assays, E4-ORF3 sufficiency and complementation, and assisted C.S. with viral mutant studies. C.C.O. analysed the array data and wrote the paper with contributions from all authors. C.C.O. was responsible for the overall conceptual design and supervision of the studies.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Additional information
Microarray data are deposited in NCBI's Gene Expression Omnibus (GSE20607).
Supplementary information
Supplementary Figures
This file contains Supplementary Figures 1-31 with legends. (PDF 4657 kb)
Supplementary Tables
This file contains Supplementary Tables 1-5. (PDF 1228 kb)
Rights and permissions
About this article
Cite this article
Soria, C., Estermann, F., Espantman, K. et al. Heterochromatin silencing of p53 target genes by a small viral protein. Nature 466, 1076–1081 (2010). https://doi.org/10.1038/nature09307
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nature09307
This article is cited by
-
Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma
BMC Cancer (2016)
-
Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression
BMC Cancer (2015)
-
Neuroblastoma: oncogenic mechanisms and therapeutic exploitation of necroptosis
Cell Death & Disease (2015)
-
p73 regulates serine biosynthesis in cancer
Oncogene (2014)
-
Cross-talk between phosphorylation and SUMOylation regulates transforming activities of an adenoviral oncoprotein
Oncogene (2013)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.